- Home
- RVT vs HCM Comparison
RVT vs HCM Comparison
Compare RVT & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RVT | HCM |
|---|---|---|
| Founded | 1986 | 2000 |
| Country | United States | Hong Kong |
| Employees | N/A | 1796 |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.3B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RVT | HCM |
|---|---|---|
| Price | $18.23 | $11.10 |
| Analyst Decision | | Sell |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.75 |
| AVG Volume (30 Days) | ★ 412.7K | 47.8K |
| Earning Date | 01-01-0001 | 03-05-2026 |
| Dividend Yield | ★ 7.32% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.95 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $20.60 |
| Revenue Next Year | N/A | $15.62 |
| P/E Ratio | $6.17 | ★ $5.49 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.78 | $9.77 |
| 52 Week High | $18.88 | $19.50 |
Technical Indicators
Market Signals| Indicator | RVT | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 50.40 | 50.38 |
| Support Level | $18.06 | $9.77 |
| Resistance Level | $18.69 | $15.59 |
| Average True Range (ATR) | 0.29 | 0.31 |
| MACD | -0.01 | 0.15 |
| Stochastic Oscillator | 54.50 | 64.71 |
Price Performance
Historical ComparisonAbout RVT Royce Value Trust Inc.
Royce Small-Cap Trust Inc is a diversified closed-end investment company that invests in equity securities of small-cap companies. The company portfolio includes sectors such as Industrials, Financials, Information Technology, Health Care, and Consumer Discretionary.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.